OTCPK:COGZ.F

Stock Analysis Report

Executive Summary

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Share Price & News

How has Cogstate's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

COGZ.F

-0.1%

US Healthcare Services

1.0%

US Market


1 Year Return

n/a

COGZ.F

15.8%

US Healthcare Services

6.7%

US Market

Return vs Industry: Insufficient data to determine how COGZ.F performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how COGZ.F performed against the US Market.


Share holder returns

COGZ.FIndustryMarket
7 Day0%-0.1%1.0%
30 Day9.1%-0.9%-1.8%
90 Dayn/a-7.5%-1.8%
1 Yearn/a16.0%15.8%9.1%6.7%
3 Year-74.1%-74.1%57.5%57.0%46.1%36.6%
5 Year-21.4%-21.4%52.5%51.4%66.9%48.6%

Price Volatility Vs. Market

How volatile is Cogstate's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cogstate undervalued based on future cash flows and its price relative to the stock market?

2.33x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate COGZ.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate COGZ.F's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: COGZ.F is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: COGZ.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate COGZ.F's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: COGZ.F is good value based on its PB Ratio (2.3x) compared to the US Healthcare Services industry average (3.5x).


Next Steps

Future Growth

How is Cogstate expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cogstate has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cogstate performed over the past 5 years?

15.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: COGZ.F is unprofitable, but has reduced losses over the past 5 years at a rate of 15.2% per year.

Accelerating Growth: Unable to compare COGZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: COGZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: COGZ.F has a negative Return on Equity (-24.68%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: COGZ.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: COGZ.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cogstate's financial position?


Financial Position Analysis

Short Term Liabilities: COGZ.F's short term assets ($9.3M) exceeds its short term liabilities ($8.8M)

Long Term Liabilities: COGZ.F's short term assets (9.3M) exceeds its long term liabilities (340.4K)


Debt to Equity History and Analysis

Debt Level: COGZ.F's debt to equity ratio (5%) is considered satisfactory

Reducing Debt: Insufficient data to determine if COGZ.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: COGZ.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: COGZ.F's debt is covered by short term assets (assets are 18.350390x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: COGZ.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: COGZ.F has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -77.5% each year


Next Steps

Dividend

What is Cogstate's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate COGZ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate COGZ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if COGZ.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COGZ.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COGZ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cogstate's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Brad O'Connor 0

13.8yrs

Tenure

US$655,042

Compensation

Mr. Bradley O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer since Ma ...


CEO Compensation Analysis

Compensation vs. Market: Brad's total compensation ($USD655.04K) is above average for companies of similar size in the US market ($USD495.80K).

Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.7yrs

Average Tenure

Experienced Management: COGZ.F's management team is considered experienced (2.7 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

53yo

Average Age

Experienced Board: COGZ.F's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$380,26510 Jul 19
FIL Limited
EntityCompany
Shares704,260
Max PriceUS$0.56

Ownership Breakdown


Management Team

  • Paul Maruff

    Chief Scientific Officer

    • Tenure: 0yrs
    • Compensation: US$416.58k
  • Brad O'Connor

    CEO, MD & Executive Director

    • Tenure: 13.8yrs
    • Compensation: US$655.04k
  • Rich Gleeson

    Chief Technology Officer

    • Tenure: 2.7yrs
    • Compensation: US$391.34k
  • Claire Newstead-Sinclair

    Finance Manager & Company Secretary

    • Tenure: 2.3yrs
  • Amy Veroff

    Principal Consultant

    • Tenure: 0yrs
  • Lammert Albers

    Chief Commercial Officer

    • Tenure: 4.9yrs
    • Compensation: US$584.38k
  • Chris Edgar

    Senior Vice President of Clinical Science

    • Tenure: 1.7yrs

Board Members

  • Rich van den Broek (53yo)

    Independent Non-Executive Director

    • Tenure: 9.2yrs
    • Compensation: US$64.79k
  • Martyn Myer (61yo)

    Non-Executive Chairman

    • Tenure: 0yrs
    • Compensation: US$101.51k
  • Jane McAloon (55yo)

    Independent Non-Executive Director

    • Tenure: 2.8yrs
    • Compensation: US$60.76k
  • Brad O'Connor

    CEO, MD & Executive Director

    • Tenure: 13.8yrs
    • Compensation: US$655.04k
  • Ingrid Player (46yo)

    Independent Non-Executive Director

    • Tenure: 0.2yrs
  • David Dolby (42yo)

    Non-Executive Director

    • Tenure: 5.9yrs
    • Compensation: US$65.15k
  • Richard Mohs

    Independent Non-Executive Director

    • Tenure: 2.8yrs
    • Compensation: US$52.98k

Company Information

Cogstate Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cogstate Limited
  • Ticker: COGZ.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$43.138m
  • Listing Market Cap: AU$29.372m
  • Shares outstanding: 148.75m
  • Website: https://www.cogstate.com

Number of Employees


Location

  • Cogstate Limited
  • 255 Bourke Street
  • Level 2
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGSASX (Australian Securities Exchange)YesOrdinary SharesAUAUDFeb 2004
COGZ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2004
CGSCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2004

Biography

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 02:32
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)